Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma
Abstract
Prospective data on maintenance therapy with bevacizumab for persons with NF2-related schwannomatosis (NF2-SWN) is lacking. In this prospective multicenter phase II study, we evaluated the efficacy, safety, and tolerability of bevacizumab for maintenance therapy in children and adults with NF2-SWN and hearing loss due to vestibular schwannomas (VS).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 03, 2023
- Source ID
- 10.1093/neuonc/noad066
Entities
People
- Bruce R. Korf
- Coretta Thomas
- D. Wade Clapp
- Girish Dhall
- Jaishri O Blakeley
- James H. Tonsgard
- Jeffrey Allen
- Jian L Campian
- Lloyd J Edwards
- Matthias A. Karajannis
- Michael J. Fisher
- Nicole J Ullrich
- Rakesh Jain
- Roger Packer
- Scott R. Plotkin
Organizations
- Boston Children's Hospital
- Children's Hospital of Philadelphia
- Children's National Hospital
- Dana Farber Harvard Cancer Center
- Harvard Medical School
- Indiana University
- Johns Hopkins University
- New York University
- United States Department of Defense
- University of Alabama
- University of Chicago
- University of Southern California
- Washington University in St. Louis